Latest Conference Articles

August 9th 2022, 9:00pm

IASLC World Conference on Lung Cancer

Although frontline treatment with avelumab resulted in a longer overall survival and progression-free survival than that observed with platinum-based chemotherapy in patients with advanced non–small cell lung cancer and high PD-L1 positivity, this difference did not achieve statistical significance.

August 9th 2022, 7:35pm

IASLC World Conference on Lung Cancer

Sunvozertinib monotherapy produced meaningful responses in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations who received prior treatment with platinum-based chemotherapy, according to pooled data from the phase 1 WU-KONG1 and WU-KONG2 trials, plus the phase 2 WU-KONG6 trial.

August 9th 2022, 7:26pm

IASLC World Conference on Lung Cancer

Brandon S. Sheffield, MD, discusses the economic cost of delaying treatment while conducting biomarker testing in non–small cell lung cancer.

August 9th 2022, 7:22pm

IASLC World Conference on Lung Cancer

Benjamin Levy, MD, discusses the efficacy findings of the combination of datopotamab deruxtecan and pembrolizumab, with or without chemotherapy, in non–small cell lung cancer.

August 9th 2022, 5:57pm

IASLC World Conference on Lung Cancer

There is an obvious way to double survival in patients with lung cancer in the next 5 years: remove barriers to screening, especially for high-risk populations.

August 9th 2022, 12:22pm

IASLC World Conference on Lung Cancer

The combination of datopotamab deruxtecan and pembrolizumab, with or without platinum-based chemotherapy, displayed promising efficacy and a manageable safety profile in patients with advanced/metastatic non–small cell lung cancer.

August 9th 2022, 11:58am

IASLC World Conference on Lung Cancer

The combination of pembrolizumab and etoposide maintained benefits in overall survival (OS) and progression-free survival vs etoposide plus placebo in patients with previously untreated extensive-stage small cell lung cancer.

August 9th 2022, 11:47am

IASLC World Conference on Lung Cancer

First-line treatment with tremelimumab, durvalumab, and chemotherapy elicited overall survival and progression-free survival benefits in patients with metastatic nonsquamous cell non–small cell lung cancer harboring STK11, KEAP1, and KRAS mutations.

August 8th 2022, 9:15pm

IASLC World Conference on Lung Cancer

Alexander I. Spira, MD, PhD, FACP, discusses additional studies investigating the use of lazertinib and amivantamab in EGFR-mutated non–small cell lung cancer.

August 8th 2022, 8:45pm

IASLC World Conference on Lung Cancer

The combination of talazoparib and temozolomide elicited an objective response rate of 39.3% in patients with extensive-stage small cell lung cancer who were relapsed or refractory to a frontline platinum-based chemotherapy regimen, according to data from a phase 2 UCLA/TRIO-US L-07 trial.

August 8th 2022, 8:26pm

IASLC World Conference on Lung Cancer

Melina Elpi Marmarelis, MD, discusses the efficacy of lazertinib and amivantamab-vmjw plus chemotherapy in patients with EGFR-mutated non–small cell lung cancer.

August 8th 2022, 6:52pm

IASLC World Conference on Lung Cancer

Temozolomide in combination with nivolumab induced a promising overall response rates in patients who previously received chemotherapy for extensive-stage small cell lung cancer.

August 8th 2022, 5:51pm

IASLC World Conference on Lung Cancer

New combinations and strategies are needed for patients with non–small cell lung cancer who progress after first-line chemoimmunotherapy after results of a retrospective analysis showed modest efficacy with second-line chemotherapy.

August 8th 2022, 4:44pm

IASLC World Conference on Lung Cancer

EGFR C797X mutations have become a leading mechanism of acquired resistance following treatment with the third-generation EGFR inhibitor osimertinib, outpacing MET amplification.

August 8th 2022, 4:10pm

IASLC World Conference on Lung Cancer

Amivantamab in combination with lazertinib plus carboplatin and pemetrexed elicited encouraging responses in pretreated patients with EGFR-mutant non–small cell lung cancer, according to findings from the phase 1 CHRYSALIS-2 trial.

August 8th 2022, 11:38am

IASLC World Conference on Lung Cancer

An overall survival trend in favor of adjuvant atezolizumab over best supportive care was observed in patients with stage II to IIIA resected non–small cell lung cancer with a PD-L1 tumor cell (TC) expression of at least 1%, with a clinically meaningful OS trend noted in those with a PD-L1 TC expression of 50% or higher.

August 8th 2022, 11:18am

IASLC World Conference on Lung Cancer

The addition of nivolumab to chemotherapy provided progression-free survival and overall survival benefits compared with chemotherapy alone in patients with stage IIIA/B non–small cell lung cancer.

August 7th 2022, 5:01pm

IASLC World Conference on Lung Cancer

The combination of pembrolizumab and lenvatinib generated promising clinical activity with a manageable safety profile in pretreated patients with malignant pleural mesothelioma.

August 7th 2022, 4:45pm

IASLC World Conference on Lung Cancer

The combination of sotorasib and the small molecule SHP2 inhibitor RMC-4630 led to an investigator-assessed objective response rate of 27% and 50% in pretreated and KRAS G12C inhibitor–naïve patients with non–small cell lung cancer, respectively.

August 7th 2022, 4:43pm

IASLC World Conference on Lung Cancer

The robust efficacy achieved with tepotinib in patients with non–small cell lung cancer harboring MET exon 14 skipping alterations was independently confirmed in data from the primary analysis of cohort C of the phase 2 VISION trial.